← Leaderboards
Frank Meyskensjr
University Of California San Diego
$159,951
Attributed
$159,951
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $33K · FY2005–10$50K$37.5K$25K$12.5K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$159,951 · 10
By mechanism
M01$159,951 · 10
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- Stephen R Seagren$330,935
- Clifford W Shults$1,572,213
- Anne R. Simoneau$160,791
Others in their field
Top investigators on “Chemoprevention”
- Charles A Coltman · Southwest Oncology Group$144,723,158
- Norman Wolmark · Nsabp Foundation, Inc.$110,141,959
- John Anthony Baron · Dartmouth College$61,176,184
- Fred M Gordin · Social And Scientific Systems, Inc.$50,695,408
- Caroline C Sigman · Ccs Associates, Inc.$26,419,788
- Jonathan White · Midwest Research Institute$24,635,824
Research focus
ChemopreventionFundingResearch PersonnelInstitutionResourcesComputer Retrieval Of Information On Scientific Projects DatabaseUnited States National Institutes Of HealthSourceMalignant NeoplasmsGrantAdverse EffectsPreventChemoprevention, ClinicalSoybeansPre-ClinicalPeptide HydrolasesClinical TrialsHead And Neck CancerHistologicProtease InhibitorLeukoplakiaLongitudinal StudiesBowman-Birk InhibitorCells
Grant awards (16)
CLINICAL TRIAL: BOWMAN-BIRK INHIBITOR CONCENTRATE AND ORAL LEUKOPLAKIA: PHASE I$345
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: BOWMAN-BIRK INHIBITOR CONCENTRATE AND ORAL LEUKOPLAKIA: PHASE I$1,133
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: DFMO/SULINDAC PHASE III$8,243
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: BOWMAN-BIRK INHIBITOR CONCENTRATE AND ORAL LEUKOPLAKIA: PHASE I$1,831
M01 · FY2008 · RR · contact PI
DFMO AND SULINDAC$7,752
M01 · FY2007 · RR · contact PI
DFMO/SULINDAC PHASE III$5,814
M01 · FY2007 · RR · contact PI
BOWMAN-BIRK INHIBITOR CONCENTRATE AND ORAL LEUKOPLAKIA: PHASE IIB TRIAL$776
M01 · FY2007 · RR · contact PI
DFMO/SULINDAC PHASE III$24,175
M01 · FY2006 · RR · contact PI
DFMO AND SULINDAC$2,628
M01 · FY2006 · RR · contact PI
BOWMAN-BIRK INHIBITOR CONCENTRATE AND ORAL LEUKOPLAKIA: PHASE IIB TRIAL$525
M01 · FY2006 · RR · contact PI
DFMO/SULINDAC PHASE III$15,874
M01 · FY2005 · RR
DFMO AND SULINDAC$12,211
M01 · FY2005 · RR
BOWMAN-BIRK INHIBITOR CONCENTRATE AND ORAL LEUKOPLAKIA: PHASE IIB TRIAL$4,885
M01 · FY2005 · RR
DFMO AND SULINDAC$51,927
M01 · FY2004 · RR
DFMO/Sulindac Phase III$15,932
M01 · FY2004 · RR
Bowman-BBIC and Oral Leukoplakia--Phase IIb Trial$5,900
M01 · FY2004 · RR